

# Multiple Sclerosis Research Studies Currently Enrolling



Fall 2010



**Multiple Sclerosis** JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or considering Treatment with Tysabri®

**Multiple Sclerosis** A study of efficacy and safety to teriflunomide in patients with relapsing MS

- 18-55 years old
- Relapsing forms of MS
- 1 relapse in the past 12 months or 2 relapse in the past 24 months

**Multiple Sclerosis** A study to evaluate the benefits of switching therapy from Copaxone or Rebif to Tysabri in subjects with Relapsing Remitting MS

- 18-60 years old
- Naïve to Tysabri
- Diagnosis of RRMS
- Treated with a stable regimen of either Copaxone or Rebif for 6 to 18 months

**Multiple Sclerosis** A study of the safety and efficacy of ONO-4641 in patients with Relapsing Remitting MS

- 18-55 years old
- Diagnosis of RRMS
- <10 lesions on MRI
- Patient must have had 1st MS symptom experience <12 years

**Multiple Sclerosis** A study to evaluate the efficacy and safety of two year treatment with teriflunomide in patients with a first clinical episode suggestive of MS

- 18-55 years old
- 1st onset of MS symptoms, occurring within 30 days, such as optic neuritis, spinal cord syndrome, brainstem/ cerebellar syndromes

Questions can be submitted to the Research Department by email: [research@neuro-institute.com](mailto:research@neuro-institute.com)

**Research Department Contacts: Myrna Shrum 704-335-6483 • Marguerite Buckley 704-331-7856**  
2607 East 7th Street, Suite 200, Charlotte, NC 28204 • [www.neuro-institute.com](http://www.neuro-institute.com)